Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Pérol D, Provençal J, Hardy-Bessard AC, Coeffic D, Jacquin JP, Agostini C, Bachelot T, Guastalla JP, Pivot X, Martin JP, Bajard A, Ray-Coquard I.

BMC Cancer. 2012 Dec 17;12:603. doi: 10.1186/1471-2407-12-603.

2.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
3.

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J.

Lancet Oncol. 2009 Jun;10(6):549-58. doi: 10.1016/S1470-2045(09)70109-3. Epub 2009 May 8.

PMID:
19428297
5.

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ.

Eur J Cancer. 2005 Jun;41(9):1278-85.

PMID:
15939263
6.

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.

Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N, Yamakage M.

J Pain Symptom Manage. 2014 Mar;47(3):542-50. doi: 10.1016/j.jpainsymman.2013.05.003. Epub 2013 Jul 12.

PMID:
23856100
7.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
8.

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.

Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C.

Support Care Cancer. 2003 Aug;11(8):522-7. Epub 2003 Jun 25.

PMID:
12827483
9.

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

Llombart-Cussac A, Ramos M, Dalmau E, García-Saenz JA, González-Farré X, Murillo L, Calvo L, Morales S, Carañana V, González A, Fernández-Morales LA, Moreno F, Casas MI, Angulo Mdel M, Cámara MC, Garcia-Mace AI, Carrasco E, Jara-Sánchez C.

Eur J Cancer. 2016 May;58:122-9. doi: 10.1016/j.ejca.2016.01.015. Epub 2016 Mar 17.

PMID:
26994459
10.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL.

Ann Oncol. 2016 Jan;27(1):172-8. doi: 10.1093/annonc/mdv482. Epub 2015 Oct 8.

11.

Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.

Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK.

Support Care Cancer. 2012 Jan;20(1):107-17. doi: 10.1007/s00520-010-1073-9. Epub 2011 Jan 22.

12.

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.

Lancet Oncol. 2009 Feb;10(2):115-24. doi: 10.1016/S1470-2045(08)70313-9. Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 Mar;11(3)226.

PMID:
19135415
13.
14.

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group.

Cancer. 2003 Jun 15;97(12):3090-8.

16.

Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life.

Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, Suárez C, Zorrilla I, Gómez J, Zabaleta P, Nocea G, Llombart-Cussac A.

Support Care Cancer. 2012 Dec;20(12):3141-8. doi: 10.1007/s00520-012-1448-1. Epub 2012 Mar 31.

PMID:
22460057
17.
18.

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR.

Ann Oncol. 1996 Nov;7(9):945-52.

PMID:
9006746
19.

Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy.

Treish I, Shord S, Valgus J, Harvey D, Nagy J, Stegal J, Lindley C.

Support Care Cancer. 2003 Aug;11(8):516-21. Epub 2003 Jun 27.

PMID:
12836088
20.

Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.

Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I.

Eur J Cancer. 2016 Apr;57:23-30. doi: 10.1016/j.ejca.2015.12.023. Epub 2016 Feb 4.

Supplemental Content

Support Center